Trial Profile
Effect of bortezomib administered once a week via subcutaneous route in patients with AL Amyloidosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Therapeutic Use
- 06 May 2015 New trial record